Ken Griffin Galecto, Inc. Put Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Put Options
4 transactions
Others Institutions Holding GLTO
# of Institutions
25Shares Held
4.04MCall Options Held
100Put Options Held
100-
Novo Holdings Hellerup, G72.5MShares$33.8 Million0.08% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny579KShares$7.84 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA221KShares$3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA214KShares$2.9 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA168KShares$2.28 Million0.0% of portfolio
About Galecto, Inc.
- Ticker GLTO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,395,700
- Market Cap $344M
- Description
- Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...